Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 9/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824190 | 0.98 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2LMNAGRM5 | |
| SCHEMBL13824116 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2LMNAGRM5 | |
| SCHEMBL19921344 | 0.91 | GRM5 (0.48) | KDM4EALDH1A1SMN1; SMN2LMNAGRM5 | |
| SCHEMBL13728247 | 0.91 | RAB9A (0.46) | KDM4EALDH1A1SMN1; SMN2LMNAGRM5 | |
| SCHEMBL19921313 | 0.88 | CD38 (0.41) | KDM4EALDH1A1SMN1; SMN2LMNAGRM5 | |
| SCHEMBL13729216 | 0.84 | TAS1R3 (0.47) | ALDH1A1 | |
| SCHEMBL19921369 | 0.83 | ADORA2A (0.45) | ALDH1A1SMN1; SMN2GAAADORA2A | |
| SCHEMBL19921427 | 0.82 | BMP1 (0.46) | KDM4EALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL19921354 | 0.81 | HIF1A (0.45) | KDM4EALDH1A1SMN1; SMN2LMNAHIF1A | |
| SCHEMBL15522335 | 0.81 | HTT (0.57) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012151567-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ADA, TYMP, ITPA | KDM4E 2486/4885ALDH1A1 1277/4885SMN1; SMN2 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.